Birmingham Capital Management Co. Inc. AL Has $5.09 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Birmingham Capital Management Co. Inc. AL grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,763 shares of the biopharmaceutical company’s stock after acquiring an additional 1,559 shares during the period. Pfizer accounts for 2.0% of Birmingham Capital Management Co. Inc. AL’s holdings, making the stock its 19th largest position. Birmingham Capital Management Co. Inc. AL’s holdings in Pfizer were worth $5,086,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Souders Financial Advisors lifted its holdings in Pfizer by 6.1% during the 2nd quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 483 shares during the last quarter. Dana Investment Advisors Inc. increased its position in Pfizer by 9.6% during the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after buying an additional 8,771 shares during the period. Founders Financial Alliance LLC lifted its holdings in shares of Pfizer by 3.6% during the second quarter. Founders Financial Alliance LLC now owns 28,419 shares of the biopharmaceutical company’s stock worth $795,000 after buying an additional 995 shares in the last quarter. 3Chopt Investment Partners LLC boosted its position in shares of Pfizer by 97.9% in the second quarter. 3Chopt Investment Partners LLC now owns 22,767 shares of the biopharmaceutical company’s stock valued at $637,000 after acquiring an additional 11,265 shares during the period. Finally, Heartland Bank & Trust Co acquired a new position in shares of Pfizer in the second quarter valued at about $596,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, September 16th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Performance

Pfizer stock opened at $28.67 on Wednesday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock has a market cap of $162.46 billion, a PE ratio of -477.83, a P/E/G ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.11. The business’s 50-day moving average price is $29.28 and its two-hundred day moving average price is $28.31.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.